| Literature DB >> 24666579 |
Sandra Mounier-Jack1, Ulla K Griffiths, Svea Closser, Helen Burchett, Bruno Marchal.
Abstract
BACKGROUND: The WHO health systems Building Blocks framework has become ubiquitous in health systems research. However, it was not developed as a research instrument, but rather to facilitate investments of resources in health systems. In this paper, we reflect on the advantages and limitations of using the framework in applied research, as experienced in three empirical vaccine studies we have undertaken. DISCUSSION: We argue that while the Building Blocks framework is valuable because of its simplicity and ability to provide a common language for researchers, it is not suitable for analysing dynamic, complex and inter-linked systems impacts. In our three studies, we found that the mechanical segmentation of effects by the WHO building blocks, without recognition of their interactions, hindered the understanding of impacts on systems as a whole. Other important limitations were the artificial equal weight given to each building block and the challenge in capturing longer term effects and opportunity costs. Another criticism is not of the framework per se, but rather how it is typically used, with a focus on the six building blocks to the neglect of the dynamic process and outcome aspects of health systems.We believe the framework would be improved by making three amendments: integrating the missing "demand" component; incorporating an overarching, holistic health systems viewpoint and including scope for interactions between components. If researchers choose to use the Building Blocks framework, we recommend that it be adapted to the specific study question and context, with formative research and piloting conducted in order to inform this adaptation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24666579 PMCID: PMC3974593 DOI: 10.1186/1471-2458-14-278
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1The WHO health system building blocks framework. Source: WHO 2007 [1].
Study characteristics
| Semi-structured interviews with key informants (national, regional, district and facility levels) | Bangladesh, Brazil, Cameroon, Ethiopia, Tajikistan, Viet Nam | |
| Reviews of secondary documents | ||
| Semi-structured interviews with key informants (national, regional and district levels) | Cameroon Ethiopia Guatemala Kenya Rwanda, Mali | |
| Questionnaire with health facility staff | ||
| Routine health service use data | ||
| Semi-structured interviews with key informants (national, district and community levels) | Nepal, India, Pakistan, Nigeria, Ethiopia, Rwanda, Angola | |
| Participant observation in polio campaigns, surveillance, and routine health post activities | ||
| Reviews of documents | ||
| Routine health service use data | ||
| DPT3 coverage data from DHS and IHME | ||
| Attended births and antenatal care coverage data from DHS |
PCV = pneumococcal conjugate vaccine; rotavirus = rotavirus vaccine; HPV = human papillomavirus vaccine; Meningitis A = Meningitis A vaccine.
Examples of questions structured according to the building blocks
| Do measles campaigns affect your capacity to reach remote areas for routine outreach services? | Has the number of outreach activities changed because you started offering the new vaccine? | Are routine immunization activities affected during polio campaign days? | |
| Do measles campaigns take staff away from routine activities? | Did the training focus solely on the new vaccine or did it cover issues relevant for other vaccines or health services too? | Are health workers’ motivation levels the same as before polio campaigns began? | |
| Was there any change in the processes for identifying high risk groups and their vaccination coverage rates? | Have immunisation documents been reprinted to include the new vaccine? If yes, has this changed the time required and data completeness? | Has the surveillance system changed as a result of polio? | |
| Have measles campaigns lead to additional infrastructure, such as waste management equipment? | Has the cold chain capacity related to the new vaccine had any impact for products other than vaccines, such as ARVs? | Have there been any changes in the cold chain infrastructure over the last 10–15 years? Are any of these changes a result of polio? | |
| Have donor funds been earmarked to measles campaigns? | Has funding requirements for the new vaccine affected the level of funding for other routine health related activities? | Is funding for polio separate from other health programs? | |
| Do you think measles campaigns tend to strengthen or weaken policy processes? | Did the planning for the new vaccine have any effect on planning activities of other health services? | In the past, have government officials given a high level of attention to routine immunization activities? Has this changed as a result of polio? |